By Nigam Arora & Dr. Natasha Arora
517% Gain
Congratulations! Arena Pharmaceuticals (ARNA), a biotech associated with marijuana, has received a $100 per share all-cash offer from Pfizer (PFE). ARNA is long from the original Arora buy signal from $16.20. At a $100 cash offer, it represents a gain of 517%.
Arena has been in the Arora MARIJUANA MODEL PORTFOLIO. We have repeatedly flagged for our subscribers that ARNA was a buyout candidate and that was one of the reasons to buy the stock. That call has now proven spot on.
To date, 169 of Arora portfolio companies have been bought out producing a fortune for long-time subscribers.
Of special note is that now three of Arora MARIJUANA MODEL PORTFOLIO companies have been bought out in 2021. The other two companies were GWPH and APHA. GW Pharmaceuticals (GWPH) was bought by Jazz Pharmaceuticals (JAZZ) and Aphria (APHA) merged with Tilray (TLRY).
ARNA is a biotech company. It’s most famous development program is for etrasimod for patients with immuno-inflammatory diseases. Arena has built a development program for etrasimod, including two Phase 3 studies in ulcerative colitis, UC, a Phase 2/3 program in Crohn’s Disease, a planned Phase 3 program in atopic dermatitis, and ongoing Phase 2 studies in eosinophilic esophagitis and alopecia areata.
Arena is associated with marijuana because of its work on APD371 which targets the CB2 receptor of the cannabinoid receptor system in the human body. The purpose is to relieve pain and replace opioids.
Pfizer – Second Booster
The Arora Report subscribers have nice gains on Pfizer. The stock is running up on speculation for the need for a second booster. For zones on PFE and what to do now, please see the prior separate post.
What To Do Now
There is a slight antitrust risk on the negative side. On the positive side is a $100 cash offer. The stock is trading up $41.84 as of this writing at $91.78.
What to do now depends on personal risk preference. The options are to take partial profits or full profits. For tracking purposes, partial profits will be taken.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
This post was just published on ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE
TRIAL TO PAID SERVICES.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
Dr. Natasha Arora
Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.
